Skip to main content
Equibles
DMRA logo

DMRA · Damora Therapeutics, Inc.

Track DMRA — free

Use DMRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DMRA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$30.48 -0.34 (-1.10%)
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 10, 2026
Market Cap
$1.90B
Shares
61.74M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$30.82 Open$30.45 Day$30.15–31.38 52W close$2.58–34.14 Avg vol 30d392K Short int4.9M · 7.9% float · 11.7d Short vol57% DataAug 2024–Aug 2026 Filing10-Q · Aug 10

Raw chart and full-history price indicators begin at the captured split on Aug 30, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 10, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.1 · calm Equity put/call 0.51
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +21%
above
Price vs 50-day avg +10%
above
RSI (14) 54
neutral
MACD trend Negative
52-week position 89%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +7%
trailing
6-month return +3%
trailing
YTD return +34%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $28 › 200d $25 — 50d above 200d
Institutional flow Accumulating
+58% holders QoQ · +51 funds added
Insider flow Distributing
Net -$7.3K over 90 days · 100% sells
Short interest Rising
7.93% of float · ▲ +4.4% MoM · 11.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
103 holders — near 2-yr high, broad support
Squeeze score 84
high risk · 0–100
Fundamentals
Strong
EPS growth +121%
Y/Y
Free cash flow $-6.9M
Balance sheet $257.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 475%
annualized · 1-yr
Max drawdown −72%
past year
ATR 6.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+21% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
54 Neutral
MACD trend
Negative Bearish
52-week position
89% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $28 › 200d $25 — 50d above 200d
Institutional flow Accumulating
+58% holders QoQ · +51 funds added
Insider flow Distributing
Net -$7.3K over 90 days · 100% sells
Short interest Rising
7.93% of float · ▲ +4.4% MoM · 11.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
103 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $3 Now $31 · 89% Range high $34
vs 200-day avg +21% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DMRA
Damora Therapeutics, Inc.
this stock
$1.90B +33.9% — — 7.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.91B +20.9% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $85.87B +8.1% +20.8% 20.7 3.3%
ARGX
Argenx SE
 $64.66B +23.6% — — 2.1%
CSLLY
Csl Ltd
 $57.97B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
103
% held
104.4%
Net QoQ
+8.5M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
38
View
Short & Settlement
Short Interest Rising
Shares short
4.9M
Days to cover
11.7d
Change
+205.2K sh
View
Short Volume
Short vol %
57%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
179
Value
$5.1K
As of
Jul 30, 2026
View
Off-Exchange
Off-exchange %
49.7%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$7.3K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-209.8M
EPS diluted
$3.98
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 10, 2026
This year
14
View
Proposed Sales
Value
$56.0K
Shares
1.8K
Filed
Aug 6, 2026
View
Exempt Offerings
Offering
$285.0M
Filed
Nov 21, 2025
View
Earnings & Events
Investor Relations
Latest news
Damora Therapeutics Reports Secon…
Published
Aug 10, 2026
View

Performance

Raw-price comparisons begin at the captured split on Aug 30, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
DMRA -0.7% +6.9% +2.6% +6.3% +33.9%
SPY -1.4% +3.6% +11.6% +2.5% +12.3%
vs SPY +0.7% +3.3% -9.0% +3.8% +21.7%
Key facts CIK 1800315 CUSIP G2646Y104 13F (30d) 102 filings 101 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)